Highlights 3D Medicines Inc.

Equities

1244

KYG8872R1011

Delayed Hong Kong S.E. Other stock markets 03:32:48 2024-05-08 am EDT			5-day change	1st Jan Change
6.04 ^HKD	-4.73%		-12.50%	-21.20%

Mar. 29	3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	MT
Mar. 28	3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	Mar. 29	MT
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	Feb. 19	MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	Feb. 19	MT
3D Medicines Inc. commences an Equity Buyback Plan for 25,605,700 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2023.	Jan. 31	CI
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	Jan. 24	CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	Jan. 24	MT
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	Dec. 27	MT
3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer	23-10-29	CI
3D Medicines Invests Over $21 Million of Surplus Cash	23-09-26	MT
3D Medicines Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
3D Medicines Expects Higher H1 Earnings	23-07-10	MT
3D Medicines Inc. Provides Earning Guidance for the Six Months Ended June 30, 2023	23-07-07	CI
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
US FDA Grants Orphan-Drug Designation to 3D Medicines' Gastric Cancer Treatment; Shares Climb 13%	23-01-16	MT
Voluntary Announcement A Phase II Study Protocol of Envafolimab for the Treatment of Dmmr Advanced Solid Tumors Has Been Allowed to Proceed by U.S. Food and Drug Administration by 3D Medicines Inc	22-12-30	CI
Gala Technology Holding Launches Up to HK$89 Million IPO	22-12-29	MT
Fed Rate Hike Snap Two-Day Gains of Hong Kong Stocks; 3 Companies Debut on the Hong Kong Stock Exchange	22-12-15	MT
3D Medicines Opens 16% Higher in Hong Kong Trading Debut	22-12-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 3D Medicines Inc.

Equities

1244

KYG8872R1011

Highlights

Filters